Akebia Therapeutics (AKBA) closed at $0.43 on November 5, 2026, down 38.8% from the previous close, on volume of 16,208,626 shares (30-day average 7,646,978).
Data as of November 5, 2026.
Seeking Alpha News (Thu, 5-Nov 7:38 AM ET)
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Thu, 5-Nov 7:10 AM ET)
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 4-Nov 6:00 PM ET)
Akebia Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 4-Nov 12:37 PM ET)
Globe Newswire (Thu, 29-Oct 8:00 AM ET)
Globe Newswire (Mon, 26-Oct 9:20 AM ET)
Globe Newswire (Wed, 7-Oct 8:00 AM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 1-Oct 4:05 PM ET)
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Akebia Therapeutics trades on the NASDAQ stock market under the symbol AKBA.
As of November 5, 2026, AKBA stock price declined to $0.43 with 16,208,626 million shares trading.
AKBA has a beta of -0.09, meaning it tends to be less sensitive to market movements. AKBA has a correlation of 0.00 to the broad based SPY ETF.
AKBA has a market cap of $117.91 million. This is considered a Micro Cap stock.
Last quarter Akebia Therapeutics reported $49 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-390,960 and met earnings estimates .
In the last 3 years, AKBA traded as high as $4.08 and as low as $.42.
The top ETF exchange traded funds that AKBA belongs to (by Net Assets): VTI, IWM, VXF, IWO, FESM.
AKBA has underperformed the market in the last year with a price return of -79.6% while the SPY ETF gained +9.7%. AKBA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -67.8% and -27.3%, respectively, while the SPY returned -4.7% and -5.2%, respectively.
AKBA support price is $.66 and resistance is $.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA shares will trade within this expected range on the day.
